Piper Jaffray
Barclays Downgrades Quest Diagnostics to Equal Weight
The investment bank cut its price target on Quest's shares and noted recently passed legislation that it believes will put pricing pressure on the company.
Fulgent Genetics Prices $26.2M Public Stock Offering
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
Fulgent Genetics to Offer $22.5M in Stock
The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million.
Genomic Health Upgraded to Overweight by Piper Jaffray
The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock.
Piper Jaffray Initiates Coverage of OncoCyte With Overweight Rating
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.